BIMIXIN ® Neomycin + Bacitracin

BIMIXIN ® is a drug based on neomycin + bacitracin

THERAPEUTIC GROUP: Antibiotic - Intestinal antimicrobial

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions BIMIXIN ® Neomycin + Bacitracin

BIMIXIN ® is indicated in the treatment of all those intestinal affections such as acute and chronic enteritis or diarrhea sustained by microorganisms sensitive to neomycin and bacitracin.

Mechanism of action BIMIXIN ® Neomycin + Bacitracin

BIMIXIN ® is an antibiotic consisting of two active ingredients united by pharmacokinetic and complementary properties from the pharmacodynamic point of view.

In fact, both the neomycin and the bacitracin taken orally, are poorly absorbed from the gastrointestinal tract, reaching intestinal lumen at concentrations such as to guarantee a significant bactericidal effect directed against both Gram + and bacteria - and also parasites belonging to the protozoan realm.

From the pharmacodynamic point of view, the action of the two antibiotics is complementary, therefore able to enhance the bactericidal effect of BIMIXIN ®

More precisely, while neomycin, as an aminoglucoside, acts by inhibiting ribosomal subunits, therefore bacitracin, the polypeptide obtained starting from Bacillus subtilis, is able to inhibit the synthesis of the bacterial wall, facilitating the osmotic lysis of the pathogen.

Studies carried out and clinical efficacy

1. NEOMYCIN AND BACYTRACINE IN THE TREATMENT OF ACUTE DIARRHEA

Acute diarrhea is one of the most common pathological manifestations of infections of the gastro-intestinal tract. The treatment with neomycin and bacitracin for 4 days, has been shown to be effective in reducing symptoms, restoring the correct stool consistency, with only a few cases of stomach pain.

2. SENSITIVITY OF THE INTESTINAL FLORA TO ANTIBIOTICS

This study, although dated, shows the importance of the effects of antibiotic therapy on the health of intestinal flora. More precisely, the resistance of bifidobacteria to the most common antibiotics used in the treatment of intestinal infectious diseases was evaluated. The study shows that these bacteria are particularly sensitive to antibiotics such as bacitracin and neomycin.

3. NEMOCIN AND BACYTRACIN IN THE PRE-OPERATIVE PHASE

The risk of bacterial infections during surgery and in the post-operative phase could be particularly dangerous for the patient's health, significantly lengthening hospitalization times. This study used the combination of neomycin and bacitracin to reduce the risk of infection, proving to be particularly useful and safe.

Method of use and dosage

BIMIXIN ® 25, 000 IU tablets of neomycin and 2, 500 bacitracin, 150, 000 IU syrup of neomycin and 15, 000 bacitracin per bottle:

the recommended dosage in intestinal diseases of bacterial origin is that of 1 - 2 tablets or 2 tablespoons of syrup every 6 - 8 hours, for no more than 3-4 days.

In any case the precise dosage must be formulated by the doctor, after a careful evaluation of the patient's physiopathological conditions.

Warnings BIMIXIN ® Neomycin + Bacitracin

The administration of BIMIXIN ® should be limited to periods not exceeding 5 days to avoid the appearance of bacterial strains resistant to the two antibiotics contained in the medicine.

It is important to remember that the presence of intestinal lesions or malabsorption syndromes, could significantly increase the gastro-intestinal absorption of the active ingredients, exposing the patient to potential nephrotoxic and ototoxic effects. In this regard it would also be advised to avoid the concomitant administration of drugs able to mask the potential side effects of the drug.

BIMIXIN ® in syrup, contains sucrose, so the intake in patients with reduced fructose tolerance or glucose / galactose malabsorption syndrome or saccharase enzyme deficiency may be associated with the appearance of unpleasant side effects.

The drug should not be administered in patients under the age of 2 years.

PREGNANCY AND BREASTFEEDING

At the moment there are no clinical trials able to effectively test the safety profile of the drug for fetal health, when taken during pregnancy or during the lactation period.

Therefore the intake of BIMIXIN ® during pregnancy and lactation should be limited to cases of real need and under strict medical supervision.

Interactions

Although both antibiotics contained in BIMIXIN ® are not absorbed from the gastro-intestinal tract, thus minimizing the risk of drug interactions, it is advisable to avoid the simultaneous administration of potentially nephrotoxic or renally active drugs, ototoxic, anticoagulants and agents capable of interfering with normal muscle function.

Contraindications BIMIXIN ® Neomycin + Bacitracin

BIMIXIN ® should not be taken by patients with kidney disease, intestinal lesions and related malabsorption and myasthenic syndromes.

Furthermore, the medicine is contraindicated in all patients with known hypersensitivity to one of the active ingredients contained in BIMIXIN ® or similar compounds.

Undesirable effects - Side effects

BIMIXIN ® therapy resulted from both various clinical trials and from well tolerated post-marketing experience, with the appearance of minor side effects such as nausea, vomiting and constipation.

More serious adverse reactions such as oliguria, albuminuria, reduced renal function, ototoxicity and dermatological reactions due to hypersensitivity, have been observed rarely in patients predisposed or with lesions of the intestinal tract.